Form 10-QSB

                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                   Quarterly Report Under Section 13 or 15 (d)
                     of the Securities Exchange Act of 1934


For Quarter Ended:            May 31, 2006
                  -----------------------------------------------
Commission File Number:             0-11050
                       ------------------------------------------

                              Mammatech Corporation
               --------------------------------------------------
             (Exact name of registrant as specified in its charter)


           Florida                              59-2181303
--------------------------------------------------------------------------------
(State or other jurisdiction of           (I.R.S. Employer
incorporation or organization)             Identification Number)


930 N.W. 8th Avenue, Gainesville, Florida         32601
--------------------------------------------------------------------------------
(Address of principal executive offices)        (Zip Code)


                                 (352) 375-0607
               --------------------------------------------------
              (Registrant's telephone number, including area code)


Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by section 13 or 15 (d) of the Securities Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the registrant
was required to file such reports), and (2) has been subject to such filing
requirements for the past ninety days. Yes [x] No [ ]

Indicate by a check mark whether the registrant is a shell company (as defined
in Rule 12b-2 of the Exchange Act)  Yes [  ]   No [ X ]

Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date:

                  Number of shares outstanding on May 31, 2006
                  --------------------------------------------

                            5,227,625 shares of which
                           310,426 are treasury shares

                              TITLE OF EACH CLASS
                              -------------------
                         Common stock $.0001 par value


<PAGE>

                              Mammatech Corporation

                                      INDEX

--------------------------------------------------------------------------------

PART I.

     FINANCIAL INFORMATION                                             PAGE NO.


     Item 1.  Financial Statements

     Balance Sheet at May 31, 2006...........................................3

     Statements of Operations for Three Months and Nine Months
     Ended May 31, 2005 and May 31, 2006.....................................4

     Statements of Cash Flows for the Nine Months
     Ended May 28, 2005 and May 28, 2006.....................................5

     Notes to Financial Statements for the Nine Months
     Ended May 31, 2006......................................................6

     Item 2.  Management's Discussion and Analysis of
     Financial Conditions and Results of Operations..........................7

     Item 3.  Controls and Procedures........................................9


PART II.     OTHER INFORMATION


     Item 6.  Exhibits and Reports on Form 8-K..............................10

     SIGNATURES.............................................................11

     EXHIBITS



                                        2
<PAGE>



                              Mammatech Corporation
                                  Balance Sheet
                                  May 31, 2006
                                   (Unaudited)

               ASSETS

Current assets:
  Cash                                                              $    10,826
  Accounts receivable - trade                                            32,486
  Inventory                                                             104,993
                                                                    -----------
      Total current assets                                              148,305
                                                                    -----------

Property and equipment, net                                             297,204
                                                                    -----------

Available for sale securities                                           496,339
Patents, trademarks and other intangibles, net                            3,123
                                                                    -----------
                                                                        499,462
                                                                    -----------

                                                                    $   944,971
                                                                    ===========
LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:
  Accounts payable and accrued expenses                             $    31,565
  Accounts payable and accrued salaries - officers                      910,955
                                                                    -----------
      Total current liabilities                                         942,520
                                                                    -----------

Stockholders' equity:
 Common stock, $.0001 par value,
  200,000,000 shares authorized, 5,227,625
  shares issued and outstanding                                             523
 Additional paid-in capital                                           2,862,206
 Accumulated (deficit)                                               (2,727,894)
                                                                    -----------
                                                                        134,835
 Treasury stock, at cost, 310,425 shares                               (148,051)
                                                                    -----------
                                                                        (13,216)
Other comprehensive income:
 Unrealized gain on marketable securities                                15,667
                                                                    -----------
                                                                          2,451
                                                                    -----------

                                                                    $   944,971
                                                                    ===========


                 See accompanying notes to financial statements.

                                       3
<PAGE>
<TABLE>
<CAPTION>

                                           Mammatech Corporation
                                  Statements of Comprehensive Operations
                         Three Months and Nine Months Ended May 31, 2005 and 2006
                                                (Unaudited)

                                                            Three Months                   Nine Months
                                                            ------------                   -----------
                                                         2005           2006           2005           2006
                                                     -----------    -----------    -----------    -----------
<S>                                                  <C>            <C>            <C>            <C>
Sales, net                                           $    68,930    $    84,666    $   207,264    $   243,651
Cost of sales                                             16,956         17,436         51,159         57,854
                                                     -----------    -----------    -----------    -----------
Gross profit                                              51,974         67,230        156,105        185,797
                                                     -----------    -----------    -----------    -----------

Selling, general and administrative expenses              87,181        106,117        309,312        294,973
                                                     -----------    -----------    -----------    -----------
(Loss) from operations                                   (35,207)       (38,887)      (153,207)      (109,176)
                                                     -----------    -----------    -----------    -----------

Other income and (expense):
  Gain (loss) on sale of investment securities             6,357        (12,647)        13,096        (11,011)
  Interest and dividend income                             6,770          5,636         25,638         26,830
                                                     -----------    -----------    -----------    -----------
                                                          13,127         (7,011)        38,734         15,819
                                                     -----------    -----------    -----------    -----------

(Loss) before income taxes                               (22,080)       (45,898)      (114,473)       (93,357)
Provision for income taxes                                  --             --             --             --
                                                     -----------    -----------    -----------    -----------
Net (loss)                                           $   (22,080)   $   (45,898)   $  (114,473)   $   (93,357)
                                                     ===========    ===========    ===========    ===========

Basic and fully diluted earnings per share:
 Net (loss)                                          $     (0.00)   $     (0.01)   $     (0.02)   $     (0.02)
                                                     ===========    ===========    ===========    ===========
 Weighted average shares outstanding                   5,202,625      5,227,625      5,202,625      5,227,625
                                                     ===========    ===========    ===========    ===========

  Net (loss)                                         $   (22,080)   $   (45,898)   $  (114,473)   $   (93,357)
   Unrealized gain (loss) from investments, net of
    income taxes                                         (32,976)        13,906          5,676         18,098
                                                     -----------    -----------    -----------    -----------
  Comprehensive (loss)                               $   (55,056)   $   (31,992)   $  (108,797)   $   (75,259)
                                                     ===========    ===========    ===========    ===========


                                       See accompanying notes to financial statements.

                                                             4
<PAGE>

                               Mammatech Corporation
                             Statements of Cash Flows
                      Nine Months Ended May 31, 2005 and 2006
                                    (Unaudited)

                                                                2005         2006
                                                             ---------    ---------

Cash flows from operating activities:
  Net cash (used in) operating activities                    $(104,590)   $ (59,502)
                                                             ---------    ---------

Cash flows from investing activities:
   Purchase of available for sale securities                  (203,297)     (26,220)
   Proceeds from the sale of available for sale securities     379,017      146,708
   Acquisition of property and equipment                      (165,000)    (129,918)
                                                             ---------    ---------
Net cash provided by (used in) investing activities             10,720       (9,430)
                                                             ---------    ---------

Cash flows from financing activities:
   Repayment of note payable                                      --           --
                                                             ---------    ---------
Net cash (used in) financing activities                           --           --
                                                             ---------    ---------

(Decrease) in cash                                             (93,870)     (68,932)
Cash and cash equivalents,
 beginning of period                                           167,844       79,758
                                                             ---------    ---------
Cash and cash equivalents,
 end of period                                               $  73,974    $  10,826
                                                             =========    =========


                  See accompanying notes to financial statements.

                                       5
</TABLE>

<PAGE>


                              MAMMATECH CORPORATION
                          NOTES TO FINANCIAL STATEMENTS
                                  MAY 31, 2006
                                   (UNAUDITED)

(1)      Basis Of Presentation

The accompanying unaudited financial statements have been prepared in accordance
with generally accepted accounting principles (GAAP) for interim financial
information and Item 310(b) of Regulation S-B. They do not include all of the
information and footnotes required by GAAP for complete financial statements. In
the opinion of management, all adjustments (consisting only of normal recurring
adjustments) considered necessary for a fair presentation have been included.

The results of operations for the periods presented are not necessarily
indicative of the results to be expected for the full year. For further
information, refer to the financial statements of the Company as of August 31,
2005, and for the two years then ended, including notes thereto included in the
Company's Form 10-KSB.

(2)      Earnings Per Share

The Company calculates net income (loss) per share as required by Statement of
Financial Accounting Standards (SFAS) 128, "Earnings per Share." Basic earnings
(loss) per share is calculated by dividing net income (loss) by the weighted
average number of common shares outstanding for the period. Diluted earnings
(loss) per share is calculated by dividing net income (loss) by the weighted
average number of common shares and dilutive common stock equivalents
outstanding. During periods when anti-dilutive commons stock equivalents are not
considered in the computation.

(3)      Inventory

Inventory is stated at the lower of cost, determined on a first in, first out
basis, or market value. Inventory consists principally of finished goods and
packaging materials.

(4)      Available For Sale Securities

Marketable securities consist of the following at May 31, 2006:

Mutual funds and equity securities with a fair market value of $496,339. The
cost basis of these securities is $480,672.

The gross realized losses on sales of available-for-sale securities were $11,011
during the nine months ended May 31, 2006. The unrealized holding gains on
available-for-sale securities included in accumulated other comprehensive income
as a component of stockholders' equity increased by $18,098 during the nine
months ended May 31, 2006, and totaled $15,667 at May 31, 2006.

During the nine months ended May 31, 2006, the Company increased its investment
in available for sale securities by $26,220 and realized net proceeds from the
sale of available for sale securities of $146,708.

                                       6

<PAGE>


               MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
         CONDITIONS AND RESULTS OF OPERATION FOR MAMMATECH CORPORATION

The following discussion should be read in conjunction with the accompanying
financial statements and notes thereto included within this Quarterly Report on
Form 10-QSB. In addition to historical information, the information in this
discussion contains forward-looking statements within the meaning of Section 27A
of the Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended. These forward-looking statements involve risks
and uncertainties, including statements regarding the Company's capital needs,
business strategy and expectations. Any statements contained herein that are not
statements of historical facts may be deemed to be forward-looking statements.
In some cases, you can identify forward-looking statements by terminology such
as "may", "will", "should", "expect", "plan", "intend", "anticipate", "believe",
estimate", "predict", "potential" or "continue", the negative of such terms or
other comparable terminology. Actual events or results may differ materially. In
evaluating these statements, you should consider various factors described in
this Quarterly Report, including the risk factors accompanying this Quarterly
Report, and, from time to time, in other reports the Company files with the
Securities and Exchange Commission. These factors may cause the Company's actual
results to differ materially from any forward-looking statement. The Company
disclaims any obligation to publicly update these statements, or disclose any
difference between its actual results and those reflected in these statements.
The information constitutes forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995.


OVERVIEW

Results for the third quarter of Fiscal 2006 were encouraging. Net sales
increased by 10.1% in comparison to the previous quarter and 22.8% relative to
the third quarter of the prior year. These gains reflect increased training
activity that the Company has experienced during this fiscal year. The operating
loss of $38,887 is 10% greater than in the prior year and up 1% from the
previous quarter. The Company continues to observe that the negative operating
income is partly a reflection of the continuing hiatus in orders from the
Company's regular military and other federal customers since the war in Iraq
began. The net loss of $45,898 also reflects, in part, the purchase of a new
manufacturing facility (see below).

The nine month sales figures are also encouraging. Net sales increased by 17.6%
compared to last year. The Company's nine month operating costs were 28.7% lower
than the similar period last year.

                                       7

<PAGE>


During the quarter, the Company trained 15 new MammaCare Specialists, and added
18 certified MammaCare BSE instructors to the ranks in Germany. The Company also
trained and certified two new MammaCare Clinical Breast Examiners. These
individuals will function in a new MammaCare Training Center that will be
operated by Alexion Brothers Hospital Network in Elk Grove, IL. The agreement
between the Company and this organization was completed during the quarter and
training of the management staff began.

During the quarter, the Company purchased for cash a new manufacturing facility
closer to the Company's headquarters building. All of the Company's
manufacturing equipment has been installed in the new facility and, at the time
of this writing, production has been substantially restored to the previous
level.

The Company also devoted substantial effort to development of an on-line version
of its clinical breast examination training program. This product is not yet
complete, but when combined with the Company's computer-based training and
evaluation system, may add substantially to the Company's penetration of the
market for professional training in breast examination.

The Company remains debt free and has no immediate liquidity problems. It
continues to seek an affiliation in the preventive health care industry that can
add value to the company's recognized technologies for early breast cancer
detection.


                                       8

<PAGE>


Item 3.  Controls and Procedures

As of the end of the period covered by this report, the Corporation's Chief
Executive Officer and Chief Financial Officer evaluated the effectiveness of the
Corporation's disclosure controls and procedures. Based on the evaluation, the
Corporation's Chief Executive Officer and Chief Financial Officer concluded that
the Corporation's disclosure controls and procedures are effective as of the end
of the period covered by this report in that information required to be
disclosed in reports filed under the Securities Exchange Act of 1934, as
amended, has been recorded, processed, summarized and reported within the
current fiscal quarter. There were no changes in the Corporation's internal
control over financial reporting that occurred during the Corporation's most
recent fiscal quarter that have materially affected, or are reasonably likely to
materially affect, the Corporation's internal control over financial reporting.

                                       9
<PAGE>


PART II - OTHER INFORMATION

Item 1.  Legal Proceedings
                           None

Item 2.  Changes in securities
                           One to twenty reverse split

Item 3.  Default upon senior securities
                           None

Item 4.  Submissions of matters to a vote of securities holders
                           None

Item 5.  Other information
                           None

Item 6.  Exhibits and Reports on Form 8-K

   (a.)  Exhibits






                                        10
<PAGE>



                                   Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

                                            MAMMATECH CORPORATION



DATE: July 20, 2006                        BY: /s/ Henry S. Pennypacker
                                            ----------------------------
                                            Henry S. Pennypacker, President
                                            and Director


                                            BY: /s/ Mary Sellers
                                            --------------------
                                            Mary Sellers, Treasurer and
                                            Chief Financial Officer


                                       11